idarubicin has been researched along with Lymphoma, Mantle-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aitini, E; Battista, R; Bendandi, M; Bocchia, M; Cellini, C; De Renzo, A; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Magagnoli, M; Moretti, L; Ronconi, F; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
2 trial(s) available for idarubicin and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Survival Rate; Treatment Outcome; Vidarabine | 1999 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |